

SECOND REGULAR SESSION

HOUSE BILL NO. 2740

103RD GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE STEINMEYER.

4420H.01I

JOSEPH ENGLER, Chief Clerk

AN ACT

To amend chapter 172, RSMo, by adding thereto one new section relating to rare pediatric disease research.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Chapter 172, RSMo, is amended by adding thereto one new section, to be
2 known as section 172.921, to read as follows:

172.921. 1. As used in this section, the following terms mean:

2 (1) "MURR", The University of Missouri research reactor;
3 (2) "Radiotheranostics", a treatment approach using radioisotopes for both
4 diagnosis and therapy;

5 (3) "Rare pediatric disease", a life-threatening or chronically debilitating disease
6 that affects fewer than two hundred thousand individuals under eighteen years of age in
7 the United States;

8 (4) "University", the University of Missouri system and its constituent
9 campuses.

10 2. The university shall establish a governance board composed of:

11 (1) Representatives from the school of medicine, MURR, Ellis Fischel Cancer
12 Center, and NextGen Precision Health;

13 (2) One appointee from each chamber of the general assembly, appointed by the
14 speaker of the Missouri house of representatives and the president pro tempore of the
15 Missouri senate;

16 (3) One patient or family advocate representative; and

17 (4) One member representing a collaborating nonprofit or industry partner.

EXPLANATION — Matter enclosed in bold-faced brackets [~~thus~~] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

18 **3. The governance board shall submit an annual public report to the general**
19 **assembly no later than December thirty-first of each year detailing:**

20 **(1) Research projects related to radiotheranostics in the treatment of rare**
21 **pediatric disease initiated and completed;**

22 **(2) Key outcomes achieved;**

23 **(3) Funds expended and leveraged; and**

24 **(4) Any legislative recommendations.**

25 **4. This section shall expire on June 30, 2030.**

✓